CordenPharma & Moderna Extend Strategic Manufacturing Services Agreement
PR84182
CordenPharma & Moderna Extend Strategic Manufacturing Services Agreement for the Supply of Lipid Excipients to be used in Moderna's Vaccine (mRNA-1273) Against the Novel Coronavirus SARS-CoV-2
LUXEMBOURG, May 28, 2020 /PRNewswire=KYODO JBN/ --
CordenPharma (
), a full-service Contract Development & Manufacturing Organization (CDMO) for
the supply of APIs, Drug Products & Pharmaceutical Packaging, announces the
signing of an amendment to their existing manufacturing agreement with Moderna,
Inc.(
) (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger
RNA (mRNA) therapeutics and vaccines to create a new generation of
transformative medicines for patients. The extension enables CordenPharma to
manufacture large-scale volumes of Moderna's lipid excipients to be used in the
manufacture of Moderna's vaccine candidate (mRNA-1273) against the novel
coronavirus (SARS-CoV-2).
Logo - https://mma.prnewswire.com/media/1173757/CordenPharma_Logo.jpg
Under the terms of the agreement, the companies will further extend their
supply relationship by expanding the manufacturing agreement originally signed
in 2016 between Moderna and CordenPharma Switzerland (
). The amended agreement now includes CordenPharma Chenôve (
) (FR) and CordenPharma Colorado (
) (US) for the manufacture of larger-scale volumes of lipids, while continuing
to draw upon CordenPharma Switzerland's long-standing reputation as a leader in
specialized lipid manufacturing (
). The expanded agreement will begin immediately in order to rapidly meet
Moderna's increasing demand over the upcoming months, with an emphasis on
securing their future long-term supply.
Juan Andres, Moderna's Chief Technical Operations and Quality Officer,
comments, "We are pleased to extend our agreement with CordenPharma. This
expansion will increase supply of lipid excipients used to manufacture our mRNA
products. We appreciate CordenPharma's global presence and CDMO expertise as we
scale manufacturing of mRNA-1273."
Dr. Michael Quirmbach, CordenPharma's President & CEO comments, "We are
thrilled to extend our long-term agreement to help support Moderna by
leveraging our strong global network of GMP manufacturing facilities across
Europe and the US to supply the immediate need of lipid excipients for their
coronavirus vaccine. We are hopeful Moderna's technology represents a positive
impact for people suffering from COVID-19 across the globe, and we are honored
to contribute to the industry as a whole."
About CordenPharma
CordenPharma, the global pharmaceutical manufacturing platform of ICIG, is a
full-service Contract Development & Manufacturing Organization for APIs, Drug
Products, and Packaging. Through cGMP facilities across Europe and the US
organized under four Technology Platforms – Peptides, Lipids & Carbohydrates,
Injectables, Highly Potent & Oncology, and Small Molecules – CordenPharma
experts translate complex projects at any stage of development into high-value
products.
Contact us (
) or visit cordenpharma.com (
).
Source – CordenPharma
CONTACT: CordenPharma Media, abby.thompson@cordenpharma.com
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
